Free Trial

Edesa Biotech (EDSA) Competitors

Edesa Biotech logo
$2.40 +0.03 (+1.27%)
Closing price 03:55 PM Eastern
Extended Trading
$2.40 +0.00 (+0.21%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EDSA vs. UNCY, IZTC, QNTM, IFRX, APLT, ABVC, ICCC, CUE, HOWL, and ADVM

Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Unicycive Therapeutics (UNCY), Invizyne Technologies (IZTC), Quantum Biopharma (QNTM), InflaRx (IFRX), Applied Therapeutics (APLT), ABVC BioPharma (ABVC), ImmuCell (ICCC), Cue Biopharma (CUE), Werewolf Therapeutics (HOWL), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry.

Edesa Biotech vs. Its Competitors

Edesa Biotech (NASDAQ:EDSA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Edesa Biotech has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.

Edesa Biotech currently has a consensus price target of $5.00, suggesting a potential upside of 108.33%. Unicycive Therapeutics has a consensus price target of $60.00, suggesting a potential upside of 1,254.40%. Given Unicycive Therapeutics' higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Edesa Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edesa Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Unicycive Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 22.6% of Edesa Biotech shares are owned by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Edesa Biotech has higher earnings, but lower revenue than Unicycive Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa BiotechN/AN/A-$6.17M-$1.59-1.51
Unicycive Therapeutics$680K82.35-$36.73M-$5.10-0.87

Edesa Biotech's return on equity of -187.01% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Edesa BiotechN/A -187.01% -78.72%
Unicycive Therapeutics N/A -277.30%-61.53%

In the previous week, Unicycive Therapeutics had 3 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 0 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.89 beat Unicycive Therapeutics' score of 0.47 indicating that Edesa Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Edesa Biotech Very Positive
Unicycive Therapeutics Neutral

Summary

Unicycive Therapeutics beats Edesa Biotech on 8 of the 14 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDSA vs. The Competition

MetricEdesa BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$16.85M$2.91B$5.52B$9.41B
Dividend YieldN/A2.45%3.80%4.04%
P/E Ratio-1.5119.8828.0419.84
Price / SalesN/A305.11429.5399.59
Price / CashN/A43.1635.8457.94
Price / Book3.937.678.125.65
Net Income-$6.17M-$55.28M$3.25B$258.00M
7 Day Performance14.83%2.50%0.97%2.09%
1 Month Performance17.65%11.70%7.36%11.13%
1 Year Performance-48.72%4.89%31.31%18.40%

Edesa Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDSA
Edesa Biotech
2.2088 of 5 stars
$2.40
+1.3%
$5.00
+108.3%
-49.5%$16.64MN/A-1.5120Positive News
Gap Up
UNCY
Unicycive Therapeutics
3.0206 of 5 stars
$4.88
-2.6%
$60.00
+1,129.5%
+5.9%$61.69MN/A-0.969High Trading Volume
IZTC
Invizyne Technologies
N/A$9.81
-2.1%
N/AN/A$61.33MN/A0.0029Gap Down
QNTM
Quantum Biopharma
N/A$21.02
+12.5%
N/AN/A$61.13MN/A-1.31N/APositive News
IFRX
InflaRx
2.791 of 5 stars
$0.89
+1.4%
$6.60
+639.9%
-45.4%$59.88M$180K-1.0960Gap Down
APLT
Applied Therapeutics
4.5429 of 5 stars
$0.42
+1.7%
$6.10
+1,348.9%
-91.7%$59.61M$460K-0.9830Positive News
ABVC
ABVC BioPharma
0.4037 of 5 stars
$3.51
-11.6%
N/A+284.9%$59.60M$510K-27.0030High Trading Volume
ICCC
ImmuCell
0.2739 of 5 stars
$6.50
+0.3%
N/A+53.8%$58.76M$26.49M-92.8470
CUE
Cue Biopharma
3.9243 of 5 stars
$0.78
+1.4%
$3.00
+286.1%
-6.4%$58.55M$9.29M-1.1660
HOWL
Werewolf Therapeutics
3.8257 of 5 stars
$1.29
+8.4%
$8.33
+546.0%
-51.4%$57.89M$1.14M-0.7740News Coverage
ADVM
Adverum Biotechnologies
4.4165 of 5 stars
$2.73
+7.5%
$23.80
+771.8%
-67.7%$57.03M$1M-0.43190

Related Companies and Tools


This page (NASDAQ:EDSA) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners